Publications by authors named "M Fornier"
Article Synopsis
- A phase II trial investigated the effectiveness of combining enzalutamide with fulvestrant in treating ER+/HER2- breast cancer to see if it reduces residual tumors at surgery compared to fulvestrant alone.
- * The combination treatment showed a significantly higher rate of achieving complete tumor response (PEPI=0) and improved immune activation in tumors compared to fulvestrant only.
- * Results indicated that the combination therapy not only lowered Ki67 levels (a marker for cancer proliferation) but also altered the tumor immune environment, suggesting increased anti-tumor activity.
CD4CD25Foxp3 regulatory T cells (Treg) have been implicated in pain modulation in various inflammatory conditions. However, whether Treg cells hamper pain at steady state and by which mechanism is still unclear. From a meta-analysis of the transcriptomes of murine Treg and conventional T cells (Tconv), we observe that the proenkephalin gene (), encoding the precursor of analgesic opioid peptides, ranks among the top 25 genes most enriched in Treg cells.
View Article and Find Full Text PDFOral minoxidil for late alopecia in cancer survivors.
Breast Cancer Res Treat
December 2024
Article Synopsis
- Late alopecia, which is incomplete hair regrowth after chemotherapy or endocrine therapy, affects women's quality of life, leading this study to investigate oral minoxidil as a treatment option.
- The study included 216 patients, primarily women with breast cancer, and found that 74% experienced improvement in hair regrowth after using oral minoxidil for about 3.5 months.
- Results showed significant increases in hair density on both the frontal and occipital areas, indicating that oral minoxidil is well-tolerated and may help cancer survivors with late alopecia.
This paper looks at experiential feedback and the technical and scientific challenges tied to the MERITE-HIPPOCAMPE cruise that took place in the Mediterranean Sea in spring 2019. This cruise proposes an innovative approach to investigate the accumulation and transfer of inorganic and organic contaminants within the planktonic food webs. We present detailed information on how the cruise worked, including 1) the cruise track and sampling stations, 2) the overall strategy, based mainly on the collection of plankton, suspended particles and water at the deep chlorophyll maximum, and the separation of these particles and planktonic organisms into various size fractions, as well as the collection of atmospheric deposition, 3) the operations performed and material used at each station, and 4) the sequence of operations and main parameters analysed.
View Article and Find Full Text PDFDenosumab is approved to prevent fragility fractures in patients with osteoporosis at high risk for fracture and to prevent bone loss in patients with breast and prostate cancer who receive endocrine therapy. The antiresorptive effect of denosumab rapidly dissipates when it is delayed or discontinued, but the risk for, and incidence of, multiple clinical vertebral fractures in patients with breast cancer after stopping denosumab is currently unclear. : We sought to identify the incidence of clinical vertebral fractures in patients with breast cancer who received at least 2 doses of denosumab (60 mg) and then discontinued the medication.
View Article and Find Full Text PDF